×
S&P 500   3,896.47 (-0.09%)
DOW   31,500.98 (+0.20%)
QQQ   290.65 (-0.62%)
AAPL   140.87 (-0.56%)
MSFT   262.20 (-1.02%)
META   168.97 (-0.31%)
GOOGL   2,286.07 (-1.32%)
AMZN   111.09 (-1.88%)
TSLA   729.95 (-0.65%)
NVDA   164.95 (-2.22%)
NIO   22.38 (-2.48%)
BABA   119.60 (+0.73%)
AMD   82.87 (-3.82%)
MU   59.45 (+1.14%)
CGC   3.74 (-1.32%)
T   20.94 (+0.77%)
GE   67.26 (+0.82%)
F   12.22 (+1.50%)
DIS   100.10 (+3.61%)
AMC   13.67 (-3.26%)
PFE   51.39 (-0.94%)
PYPL   74.98 (-1.26%)
NFLX   186.29 (-1.51%)
S&P 500   3,896.47 (-0.09%)
DOW   31,500.98 (+0.20%)
QQQ   290.65 (-0.62%)
AAPL   140.87 (-0.56%)
MSFT   262.20 (-1.02%)
META   168.97 (-0.31%)
GOOGL   2,286.07 (-1.32%)
AMZN   111.09 (-1.88%)
TSLA   729.95 (-0.65%)
NVDA   164.95 (-2.22%)
NIO   22.38 (-2.48%)
BABA   119.60 (+0.73%)
AMD   82.87 (-3.82%)
MU   59.45 (+1.14%)
CGC   3.74 (-1.32%)
T   20.94 (+0.77%)
GE   67.26 (+0.82%)
F   12.22 (+1.50%)
DIS   100.10 (+3.61%)
AMC   13.67 (-3.26%)
PFE   51.39 (-0.94%)
PYPL   74.98 (-1.26%)
NFLX   186.29 (-1.51%)
S&P 500   3,896.47 (-0.09%)
DOW   31,500.98 (+0.20%)
QQQ   290.65 (-0.62%)
AAPL   140.87 (-0.56%)
MSFT   262.20 (-1.02%)
META   168.97 (-0.31%)
GOOGL   2,286.07 (-1.32%)
AMZN   111.09 (-1.88%)
TSLA   729.95 (-0.65%)
NVDA   164.95 (-2.22%)
NIO   22.38 (-2.48%)
BABA   119.60 (+0.73%)
AMD   82.87 (-3.82%)
MU   59.45 (+1.14%)
CGC   3.74 (-1.32%)
T   20.94 (+0.77%)
GE   67.26 (+0.82%)
F   12.22 (+1.50%)
DIS   100.10 (+3.61%)
AMC   13.67 (-3.26%)
PFE   51.39 (-0.94%)
PYPL   74.98 (-1.26%)
NFLX   186.29 (-1.51%)
S&P 500   3,896.47 (-0.09%)
DOW   31,500.98 (+0.20%)
QQQ   290.65 (-0.62%)
AAPL   140.87 (-0.56%)
MSFT   262.20 (-1.02%)
META   168.97 (-0.31%)
GOOGL   2,286.07 (-1.32%)
AMZN   111.09 (-1.88%)
TSLA   729.95 (-0.65%)
NVDA   164.95 (-2.22%)
NIO   22.38 (-2.48%)
BABA   119.60 (+0.73%)
AMD   82.87 (-3.82%)
MU   59.45 (+1.14%)
CGC   3.74 (-1.32%)
T   20.94 (+0.77%)
GE   67.26 (+0.82%)
F   12.22 (+1.50%)
DIS   100.10 (+3.61%)
AMC   13.67 (-3.26%)
PFE   51.39 (-0.94%)
PYPL   74.98 (-1.26%)
NFLX   186.29 (-1.51%)
NASDAQ:CVET

Covetrus Stock Forecast, Price & News

$20.76
+0.01 (+0.05%)
(As of 06/28/2022 11:01 AM ET)
Add
Compare
Today's Range
$20.74
$20.77
50-Day Range
$13.80
$20.82
52-Week Range
$13.39
$29.01
Volume
15,606 shs
Average Volume
1.70 million shs
Market Capitalization
$2.89 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$23.71
30 days | 90 days | 365 days | Advanced Chart

Receive CVET Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Covetrus and its competitors with MarketBeat's FREE daily newsletter.

CVET Stock Forecast (MarketRank)

Overall MarketRank

2.19 out of 5 stars

Computer And Technology Sector

352nd out of 936 stocks

Drug Stores & Proprietary Stores Industry

3rd out of 9 stocks

Analyst Opinion: 3.0Community Rank: 3.6Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 1.9 5 -4 -3 -2 -1 -
Covetrus logo

About Covetrus (NASDAQ:CVET)

Covetrus, Inc., together with its subsidiaries, operates as an animal-health technology and services company. It engages in the sale of animal-health consumable products, including proprietary and Covetrus branded products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products, parasiticides, and vitamins and supplements to wholesale and retail customers. The company also offers value-added solutions, such as inventory management and e-commerce, as well as continuing education services for practitioners. In addition, it provides practice management software, data-driven applications, client communications tools, and related services to increase staff efficiency and enhance business health; and solutions that integrate with its software platforms, including client communication services, reminders, data backup services, hardware sales and support, and credit card processing services for veterinary practitioners and animal-health clinics. Further, the company engages in the distribution of finished goods pharmacy and specialty pharmaceutical compounding products, as well as offers shipping, manufacturer incentives, service fees, and data integration and support services. It serves animal-health and veterinary practices, and clinics in the companion-animal, equine, and large-animal markets primarily in North America, Europe, and the Asia Pacific. The company was formerly known as HS Spinco, Inc. Covetrus, Inc. was incorporated in 2018 and is headquartered in Portland, Maine.

CVET Stock News Headlines

Covetrus (NASDAQ:CVET) Downgraded to Hold at Stifel Nicolaus
See More Headlines

Industry, Sector and Symbol

Industry
Drug stores & proprietary stores
Sub-Industry
N/A
Current Symbol
NASDAQ:CVET
Fax
N/A
Employees
5,710
Year Founded
N/A

Company Calendar

Last Earnings
5/05/2022
Today
6/28/2022
Next Earnings (Estimated)
8/04/2022
Fiscal Year End
12/31/2022

Price Target and Rating

Average Stock Price Forecast
$23.71
High Stock Price Forecast
$30.00
Low Stock Price Forecast
$16.00
Forecasted Upside/Downside
+14.2%
Consensus Rating
Hold
Rating Score (0-4)
2
Research Coverage
8 Analysts

Profitability

Net Income
$-54 million
Pretax Margin
-0.89%

Debt

Sales & Book Value

Annual Sales
$4.58 billion
Cash Flow
$2.19 per share
Book Value
$10.97 per share

Miscellaneous

Free Float
138,570,000
Market Cap
$2.89 billion
Optionable
Not Optionable
Beta
1.92














Covetrus Frequently Asked Questions

Should I buy or sell Covetrus stock right now?

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Covetrus in the last twelve months. There are currently 1 sell rating, 6 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" Covetrus stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CVET, but not buy additional shares or sell existing shares.
View analyst ratings for Covetrus
or view top-rated stocks.

What is Covetrus' stock price forecast for 2022?

8 brokers have issued 1-year target prices for Covetrus' stock. Their CVET stock forecasts range from $16.00 to $30.00. On average, they expect Covetrus' stock price to reach $23.71 in the next year. This suggests a possible upside of 14.2% from the stock's current price.
View analysts' price targets for Covetrus
or view top-rated stocks among Wall Street analysts.

How has Covetrus' stock performed in 2022?

Covetrus' stock was trading at $19.97 at the beginning of 2022. Since then, CVET shares have increased by 4.0% and is now trading at $20.76.
View the best growth stocks for 2022 here
.

Are investors shorting Covetrus?

Covetrus saw a decline in short interest in May. As of May 31st, there was short interest totaling 2,750,000 shares, a decline of 15.4% from the May 15th total of 3,250,000 shares. Based on an average daily volume of 1,780,000 shares, the days-to-cover ratio is currently 1.5 days. Approximately 2.6% of the shares of the stock are sold short.
View Covetrus' Short Interest
.

When is Covetrus' next earnings date?

Covetrus is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for Covetrus
.

How were Covetrus' earnings last quarter?

Covetrus, Inc. (NASDAQ:CVET) issued its quarterly earnings data on Thursday, May, 5th. The company reported $0.25 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.22 by $0.03. The firm had revenue of $1.15 billion for the quarter, compared to the consensus estimate of $1.15 billion. Covetrus had a positive trailing twelve-month return on equity of 1.92% and a negative net margin of 0.87%. Covetrus's revenue was up 4.2% on a year-over-year basis. During the same period in the prior year, the company earned $0.16 EPS.
View Covetrus' earnings history
.

Who are Covetrus' key executives?

Covetrus' management team includes the following people:
  • Mr. Benjamin Wolin, Pres, CEO & Director (Age 46, Pay $1.02M) (LinkedIn Profile)
  • Mr. Matthew J. Foulston, Exec. VP & Global CFO (Age 57, Pay $624.66k)
  • Ms. Georgina Wraight, Exec. VP & Pres of Global Technology Solutions (Age 47, Pay $563.4k)
  • Mr. Dustin k. Finer, Chief Admin. Officer (Age 52, Pay $552.67k) (LinkedIn Profile)
  • Mr. Matthew Malenfant, Chief Commercial Officer (Age 60, Pay $533.62k)
  • Ms. Rebecca Kidd, Head of Operations & Operational Excellence (Age 53)
  • Mr. Andrew B. Coxhead, VP, Corp. Controller & Chief Accounting Officer (Age 53)
  • Mr. Nicholas Michael Jansen, VP of Investor Relations
  • Ms. Ditte Marstrand Wulf, Global Chief HR Officer (Age 51)
  • Mr. Russell Cooke, Sr. VP & Operational CFO (Age 56)

What is Benjamin Wolin's approval rating as Covetrus' CEO?

25 employees have rated Covetrus CEO Benjamin Wolin on Glassdoor.com. Benjamin Wolin has an approval rating of 89% among Covetrus' employees.

What other stocks do shareholders of Covetrus own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Covetrus investors own include Pfizer (PFE), NVIDIA (NVDA), Advanced Micro Devices (AMD), AT&T (T), Activision Blizzard (ATVI), Boeing (BA), Chegg (CHGG), Enphase Energy (ENPH), Enterprise Products Partners (EPD) and Livongo Health (LVGO).

What is Covetrus' stock symbol?

Covetrus trades on the NASDAQ under the ticker symbol "CVET."

Who are Covetrus' major shareholders?

Covetrus' stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (11.83%), Vanguard Group Inc. (8.28%), Wellington Management Group LLP (6.00%), JPMorgan Chase & Co. (3.55%), Freshford Capital Management LLC (2.78%) and State Street Corp (2.76%). Company insiders that own Covetrus stock include Anthony C Jr Providenti, Benjamin Shaw, Benjamin Wolin, David Stuart Hinton, Dustin Finer, Edward Mcnamara, Erin Powers Brennan, Georgina Wraight, Herbert Virgin, Laura J Phillips, Michael Ellis and Timothy Ludlow.
View institutional ownership trends for Covetrus
.

Which institutional investors are selling Covetrus stock?

CVET stock was sold by a variety of institutional investors in the last quarter, including Schf GPE LLC, Frontier Capital Management Co. LLC, Goldman Sachs Group Inc., Bank of America Corp DE, Allianz Asset Management GmbH, Palisade Capital Management LLC NJ, Madison Asset Management LLC, and Freshford Capital Management LLC. Company insiders that have sold Covetrus company stock in the last two years include Anthony C Jr Providenti, Benjamin Wolin, David Stuart Hinton, Dustin Finer, Edward Mcnamara, Georgina Wraight, Herbert Virgin, Laura J Phillips, Michael Ellis, and Timothy Ludlow.
View insider buying and selling activity for Covetrus
or view top insider-selling stocks.

Which institutional investors are buying Covetrus stock?

CVET stock was purchased by a variety of institutional investors in the last quarter, including Select Equity Group L.P., Fort Washington Investment Advisors Inc. OH, Dimensional Fund Advisors LP, Wellington Management Group LLP, Kovitz Investment Group Partners LLC, Vanguard Group Inc., Royce & Associates LP, and Charles Schwab Investment Management Inc..
View insider buying and selling activity for Covetrus
or or view top insider-buying stocks.

How do I buy shares of Covetrus?

Shares of CVET can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Covetrus' stock price today?

One share of CVET stock can currently be purchased for approximately $20.76.

How much money does Covetrus make?

Covetrus (NASDAQ:CVET) has a market capitalization of $2.89 billion and generates $4.58 billion in revenue each year. The company earns $-54 million in net income (profit) each year or ($0.300010) on an earnings per share basis.

How many employees does Covetrus have?

Covetrus employs 5,710 workers across the globe.

How can I contact Covetrus?

Covetrus' mailing address is 7 CUSTOM HOUSE STREET, PORTLAND ME, 04101. The official website for Covetrus is www.henryscheinvet.com. The company can be reached via phone at (888) 280-2221 or via email at [email protected].

This page (NASDAQ:CVET) was last updated on 6/28/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.